SCHEMBL21058397

SCHEMBL21058397

CCCC(=O)N[C@H]1C(O)O[C@H](COC(=O)C(NC(=O)OC(C)(C)C)C(C)C)[C@@H](O)[C@@H]1O

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 4/20 0.35
▸ CTSS P25774 2/20 0.35
▸ PYGB P11216 1/20 0.34
▸ CTSL P07711 2/20 0.32
▸ CA1 P00915 1/20 0.32
▸ CA2 P00918 1/20 0.32
▸ CA7 P43166 1/20 0.32
▸ PSENEN Q9NZ42 1/20 0.32
▸ KLK5 Q9Y337 1/20 0.32
▸ CTSB P07858 1/20 0.32
▸ TLR4 O00206 1/20 0.31
▸ AMDHD2 Q9Y303 1/20 0.31
▸ PREP P48147 1/20 0.30
▸ MAPK1 P28482 1/20 0.30
▸ CYP2D6 P10635 2/20 0.30
▸ KDM4E B2RXH2 1/20 0.30
▸ LMNA P02545 1/20 0.30
▸ CYP2C19 P33261 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21137891 1.00 CTSK (0.35) CTSKCTSSPYGBCTSLCA1
SCHEMBL21137896 0.92 SDCBP (0.32) CTSKCTSSPYGBKLK5
SCHEMBL25957442 0.87 CTSK (0.36) CTSKCTSSPYGBTLR4AMDHD2
SCHEMBL31353010 0.87 CAPN1 (0.40) CTSKCTSSPYGBCTSLCTSB
SCHEMBL21138667 0.85 PYGB (0.36) PYGBTLR4AMDHD2MAPK1CYP2D6
SCHEMBL21137968 0.85 PYGB (0.38) PYGBTLR4AMDHD2MAPK1CYP2D6
Hydrochloric Acid SCHEMBL29777456 0.84 PYGB (0.36) PYGBTLR4AMDHD2MAPK1CYP2D6
SCHEMBL28514916 0.81 PYGB (0.42) CTSKCTSSPYGBCA1CA2
SCHEMBL21058353 0.80 ACE (0.48) CTSKCTSSCTSLKLK5CTSB
SCHEMBL21137980 0.79 PYGB (0.40) PYGBCA1CA2TLR4AMDHD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552823-B2 Glucosamine derivatives and pharmaceutical uses thereof Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2026-02-17 — — US disclosed
US-20250353870-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2025-11-20 — — US disclosed
US-12312378-B2 Glucosamine derivatives for the prevention or treatment of joint disorders Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2025-05-27 — — US disclosed
US-20240051982-A1 GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2024-02-15 — — US disclosed
US-11718636-B2 Glucosamine derivatives for the prevention or treatment of joint disorders Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2023-08-08 — — US disclosed
US-20230227488-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2023-07-20 — — US disclosed
US-11591358-B2 Glucosamine derivatives and pharmaceutical uses thereof Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2023-02-28 — — US disclosed
CN-115594724-A Glucosamine derivatives for preventing or treating joint diseases 润佳(苏州)医药科技有限公司(CN) 2023-01-13 — — CN disclosed
CN-115215911-A Glucosamine derivative, composition thereof and medical application thereof 润佳(苏州)医药科技有限公司 2022-10-21 — — CN disclosed
CN-111971290-B Glucosamine derivatives for preventing or treating joint diseases 润佳(苏州)医药科技有限公司 2022-10-14 — — CN disclosed
CN-109929001-B Glucosamine derivative, composition thereof and medical application thereof 润佳(苏州)医药科技有限公司 2022-07-08 — — CN disclosed
US-20210079033-A1 GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2021-03-18 — — US disclosed
CN-111971290-A Glucosamine derivatives for preventing or treating joint diseases 润佳(苏州)医药科技有限公司 2020-11-20 — — CN disclosed
US-20190185502-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF RISEN (SUZHOU) PHARMA TECH CO, LTD. (CN) 2019-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250353870-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF OGT, UGGT1, GLA CTSK 331/4885CTSS 674/4885PYGB 601/4885
US-20210079033-A1 GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS OGT, UGGT1, GLA CTSK 577/4885CTSS 1085/4885PYGB 760/4885
US-20240051982-A1 GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS OGT, UGGT1, FUT6 CTSK 493/4885CTSS 1129/4885PYGB 802/4885
US-11718636-B2 Glucosamine derivatives for the prevention or treatment of joint disorders OGT, UGGT1, GLA CTSK 577/4885CTSS 1085/4885PYGB 760/4885
US-12552823-B2 Glucosamine derivatives and pharmaceutical uses thereof SOST, FUT6, SLC5A1 CTSK 874/4885CTSS 1006/4885PYGB 675/4885
US-20230227488-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF OGT, UGGT1, GLA CTSK 331/4885CTSS 674/4885PYGB 601/4885
US-20190185502-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF OGT, UGGT1, GLA CTSK 331/4885CTSS 674/4885PYGB 601/4885
US-11591358-B2 Glucosamine derivatives and pharmaceutical uses thereof OGT, UGGT1, GLA CTSK 331/4885CTSS 674/4885PYGB 601/4885
US-12312378-B2 Glucosamine derivatives for the prevention or treatment of joint disorders OGT, UGGT1, FUT6 CTSK 493/4885CTSS 1129/4885PYGB 802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback